Source: governmentciomedia.com The Government Accountability Office identified to lawmakers potentialĀ use cases for machine learningĀ in drug development to help drive efficiencies and cost savings. The Food and Drug Administration has been tracking the use of artificial intelligence in drug development. Although the FDA does not currently have a regulatory policy around machine learning in drug development, GAO Read More

Read More

Source: healthitanalytics.com January 22, 2020 – Machine learning algorithms have the potential to accelerate and refine the drug development process, but the industry should expand data access and create consistent data standards to ensure drug companies can fully leverage these tools, according to a report from the Government Accountability Office (GAO). Drug companies spend ten Read More

Read More
Artificial Intelligence